Piramal Pharma Ltd (NSE: PPLPHARMA, BSE: 543635) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹26,284 Cr, it ranks #311 by market cap among the 6,137 Indian listed companies on FinBizNet, and #4 of 63 in Pharmaceuticals. At ₹191.07 (as of 25 Oct 2026), the share price is 17.6% below its 52-week high of ₹231.93 and 44.4% above its 52-week low of ₹132.30. The share price is down 1.6% over one year and up 5.4% over three months.
| Current Price | ₹191.07 |
|---|---|
| Market Cap | ₹26,284 Cr |
| NSE Symbol | PPLPHARMA |
| BSE Code | 543635 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | -79 |
| Return on Equity | -4.00% |
| Return on Assets | 0.36% |
| 52-Week Range | ₹132.30 – ₹231.93 |
| 1-Year Price Change | -1.6% |
| 3-Month Price Change | +5.4% |
| Beta (1Y) | 0.38 |
| Dividend Yield | 0.00% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.piramalpharma.com |
| Revenue | ₹2,270 Cr |
|---|---|
| Net Profit | ₹-89 Cr |
| Net Margin | -3.9% |
| EPS (Basic) | ₹-0.52 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
1. Pharma-This segment engages in the pharmaceuticals business. 2. NA-NA 3. NA-NA 4. NA-NA
1. Pharma-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹55,577 Cr | 35.5 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,591 Cr | 39 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹34,533 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹26,284 Cr | -79 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹24,972 Cr | 97.6 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹17,484 Cr | 26.9 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹17,448 Cr | 24.1 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,877 Cr | 24.8 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,915 Cr | 80.6 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Piramal Pharma Ltd is trading at ₹191.07, with a market capitalisation of ₹26,284 Cr.
Piramal Pharma Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Piramal Pharma Ltd has a P/E of -79 and a return on equity of -4.00%.
Piramal Pharma Ltd is listed on the NSE under the symbol PPLPHARMA and on the BSE under the scrip code 543635.
Piramal Pharma Ltd's share price is down 1.6% over one year and up 5.4% over three months. Its 52-week range is ₹132.30 to ₹231.93.
In Q1 FY27, Piramal Pharma Ltd reported revenue of ₹2,270 Cr and net profit of ₹-89 Cr, with basic EPS of ₹-0.52 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.